Susan L. Cohn

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 26 papers. Top paper: “Association between end‐induction response according to the revised International Neuroblastoma Response Criteria (INRC) and outcome in high‐risk neuroblastoma patients”.

Association between end‐induction response according to the revised International Neuroblastoma Response Criteria (INRC) and outcome in high‐risk neuroblastoma patients

Pediatric Blood & Cancer(2020)10.1002/pbc.28390

N/A

0.767DataRank · unranked

13 citations

Kathryn Laurie, Kristen Wroblewski, Mark A. Applebaum, Susan L. Cohn, Erin K. Barr

The MYCN Enigma: Significance of MYCN Expression in Neuroblastoma

Cancer Research(2006)10.1158/0008-5472.can-05-0854

N/A

0.675DataRank · unranked

89 citations

Huaqing Zhao, Bing Kung, David Y. Kim, Sakeenah L. Hicks, Susan L. Cohn +5 more

Tailoring Therapy for Children With Neuroblastoma on the Basis of Risk Group Classification: Past, Present, and Future

JCO Clinical Cancer Informatics(2020)10.1200/cci.20.00074

N/A

0.646DataRank · unranked

73 citations

Sara M. Federico, Wendy B. London, Arlene Naranjo, Meredith S. Irwin, Samuel L. Volchenboum +2 more

Factors influencing parents’ choice of palliative treatment goals for children with relapsed or refractory neuroblastoma: A multi‐site longitudinal survey study

Cancer(2023)10.1002/cncr.35149

N/A

0.360DataRank · unranked

10 citations

Jesse Smith, Yiwang Zhou, Rochelle Bagatell, Justin N. Baker, Susan L. Cohn +10 more

Outcomes and toxicities in patients (pts) non-randomly assigned to immunotherapy Children’s Oncology Group (COG) ANBL0032.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.10523

N/A

0DataRank · unranked

0 citations

Andrew L. Gilman, M. Fevzi Özkaynak, Arlene Naranjo, Wendy B. London, Sheena C. Tenney +11 more

Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-3909

N/A

0DataRank · unranked

216 citations

Andrew L. Gilman, M. Fevzi Özkaynak, Arlene Naranjo, Mitchell B. Diccianni, Jacek Gan +14 more

Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002417

N/A

0DataRank · unranked

46 citations

Stefani Spranger, Kyle M. Hernandez, Yuanyuan Zha, Peter Pytel, Jason J. Luke +5 more

Late morbidity and mortality among survivors of neuroblastoma treated with contemporary therapy: A report from the Childhood Cancer Survivor Study.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.10044

N/A

0DataRank · unranked

3 citations

Pamela J. Goodman, Wendy M. Leisenring, Lisa Diller, Susan L. Cohn, Emily S. Tonorezos +13 more

Predicting response to chemotherapy in neuroblastoma using deep learning: A report from the International Neuroblastoma Risk Group.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.10039

N/A

0DataRank · unranked

2 citations

Diana Michael, Liu Liu, Nicholas Feinberg, Meaghan Granger, Arlene Naranjo +5 more

Efficacy of post‐induction therapy for high‐risk neuroblastoma patients with end‐induction residual disease

Cancer(2022)10.1002/cncr.34263

N/A

0DataRank · unranked

13 citations

Mark A. Applebaum, Theodore Karrison, Akosua Y. Oppong, Cindy Yuan, Katherine R. Berg +14 more

Survival of patients with neuroblastoma before versus after reduction of therapy due to the change in age cut-off from 12 to 18 months in Children’s Oncology Group (COG) risk stratification.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.10013

N/A

0DataRank · unranked

1 citations

Hannah Bender, Meredith S. Irwin, Michael D. Hogarty, Robert P. Castleberry, John M. Maris +4 more

Adrenergic and mesenchymal signatures are identifiable in cell‐free DNA and correlate with metastatic disease burden in children with neuroblastoma

Pediatric Blood & Cancer(2023)10.1002/pbc.30735

N/A

0DataRank · unranked

14 citations

Maria E. Kaufman, Kelley Moore, Mohansrinivas Chennakesavalu, Rachel TerHaar, Gepoliano Chaves +5 more

T-cell inflammation is prognostic of survival in patients with high-risk neuroblastoma enriched for an adrenergic signature

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.06.26.546541

N/A

0DataRank · unranked

2 citations

Omar R. Vayani, Kelley Moore, Alexandre Chlenski, Tong Wu, Gepoliano Chavez +6 more

Data from Thrombospondin-1 Peptide ABT-510 Combined with Valproic Acid Is an Effective Antiangiogenesis Strategy in Neuroblastoma

(2023)10.1158/0008-5472.c.6494820

N/A

0DataRank · unranked

0 citations

Yufeng Tian, Shuqing Liu, Rana Zeine, Alexandre Chlenski, Helen R. Salwen +3 more

Data from Thrombospondin-1 Peptide ABT-510 Combined with Valproic Acid Is an Effective Antiangiogenesis Strategy in Neuroblastoma

(2023)10.1158/0008-5472.c.6494820.v1

N/A

0DataRank · unranked

0 citations

Yufeng Tian, Shuqing Liu, Rana Zeine, Alexandre Chlenski, Helen R. Salwen +3 more

Data from Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032

(2023)10.1158/1078-0432.c.6531294

N/A

0DataRank · unranked

0 citations

Andrew L. Gilman, M. Fevzi Özkaynak, Arlene Naranjo, Mitchell B. Diccianni, Jacek Gan +14 more

Data from Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032

(2023)10.1158/1078-0432.c.6531294.v1

N/A

0DataRank · unranked

0 citations

Andrew L. Gilman, M. Fevzi Özkaynak, Arlene Naranjo, Mitchell B. Diccianni, Jacek Gan +14 more

Small-molecule inhibition of the METTL3/METTL14 complex suppresses neuroblastoma tumor growth and promotes differentiation

Cell Reports(2024)10.1016/j.celrep.2024.114165

N/A

0DataRank · unranked

39 citations

Mohansrinivas Chennakesavalu, Pingluan Wang, Zhiwei Jiang, Hui‐Lung Sun, Peizhe Ren +16 more

Artificial intelligence-based morphologic classification and molecular characterization of neuroblastic tumors from digital histopathology

npj Precision Oncology(2024)10.1038/s41698-024-00745-0

N/A

0DataRank · unranked

16 citations

Emma Dyer, Monica Pomaville, Kristina Doytcheva, James M. Dolezal, Sara Kochanny +16 more

Evaluation of Image-Defined Risk Factor (IDRF) Assessment in Patients With Intermediate-risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531

Journal of Pediatric Surgery(2024)10.1016/j.jpedsurg.2024.161896

N/A

0DataRank · unranked

6 citations

E. Stanton Adkins, Peter Mattei, Fredric A. Hoffer, Sandra L. Wootton‐Gorges, Wendy B. London +14 more

Improvements in Children’s Oncology Group neuroblastoma risk stratification through a change in age cut-off and use of INRGSS

Translational Pediatrics(2024)10.21037/tp-24-319

N/A

0DataRank · unranked

2 citations

Hannah Bousquet, Meredith S. Irwin, Michael D. Hogarty, Susan L. Cohn, Wendy B. London

Outcomes of patients with intermediate‐risk neuroblastoma presenting with motor deficits relating to intraspinal tumor extension: A report from the Children's Oncology Group study ANBL0531

Pediatric Blood & Cancer(2024)10.1002/pbc.31407

N/A

0DataRank · unranked

1 citations

Howard M. Katzenstein, Arlene Naranjo, Sheena C. Tenney, Lulu Chen, Wendy B. London +11 more

Artificial intelligence-based morphologic classification and molecular characterization of neuroblastic tumors from digital histopathology

Research Square(2024)10.21203/rs.3.rs-4396782/v1

N/A

0DataRank · unranked

1 citations

Siddhi Ramesh, Emma Dyer, Monica Pomaville, Kristina Doytcheva, James M. Dolezal +13 more

Paraneoplastic opsoclonus myoclonus syndrome associated with inflammatory myofibroblastic tumor in a pediatric patient

Pediatric Blood & Cancer(2020)10.1002/pbc.28218

N/A

0DataRank · unranked

1 citations

Amir M. Siddiqui, Jefree J. Schulte, Susan L. Cohn, Karyn Gerstle

Randomized phase II trial of MIBG versus MIBG/vincristine/irinotecan versus MIBG/vorinostat for relapsed/refractory neuroblastoma: A report from the New Approaches to Neuroblastoma Therapy Consortium.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.10500

N/A

0DataRank · unranked

4 citations

Meaghan Granger, Susan Groshen, Denice Tsao‐Wei, Anasheh Shamirian, Scarlett Czarnecki +15 more

Regional Variation in HIV Clinical Trials Participation in the United States

UNC Libraries(2020)10.17615/df82-mf86

N/A

0DataRank · unranked

4 citations

Michelle Floris-Moore, Susan L. Cohn, Supriya Krishnan, Michelle Cespedes, Kimberly G. Smith +2 more